---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011909"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:38:52.479812+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Aprea Therapeutics files updated corporate slide deck; no material new data disclosed

## Summary
- Filed updated corporate presentation dated September 2025 under Item 8.01.
- Presentation titled 'Precision Oncology Through Synthetic Lethality' continues DDR inhibition focus.
- No specific financial, clinical, or pipeline milestones were evident from the excerpt provided.

## SEC filing metadata
- accession: 0001558370-25-011909
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837025011909/0001558370-25-011909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837025011909/apre-20250908x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011909
- JSON: https://secwatch.observer/filing/0001558370-25-011909.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.